ELV Stock Analysis — Elevance Health
Sector: Healthcare
AI Verdict
ELV trades cheap for the growth you're getting, and its scale-driven moat makes the double-digit earnings forecast look credible unless regulatory winds shift.
Competitive Moat
Elevance Health operates one of the largest managed care organizations in the U.S., leveraging scale to negotiate favorable rates with providers and maintain sticky relationships with large employer and government clients. Its entrenched position in government-sponsored health plans and broad provider network make it difficult for new entrants to disrupt its core business.
Summary
ELV is notable for trading at just 13.2x next year's earnings despite double-digit expected EPS growth.
Where It Stands
ELV has delivered a 36.70% one-year return, trades at 13.2x forward earnings versus the healthcare sector's 22x median, and its RSI of 67.6 signals elevated momentum with some pullback risk.
Key Metrics
- RSI: 67.6 — Near Overbought
- Trailing P/E: 15.4x
- Forward P/E: 13.2x
- PEG Ratio: 0.92
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- Market Cap: $86.6B
- Dividend Yield: 0.02%
- 1-Year Return: 36.70%
- 52-Week High: $436.24
- 52-Week Low: $274.84
Analyst Consensus
19 Buy · 10 Hold · 0 Sell (29 analysts)
Bull Case
With analysts forecasting 16.7% EPS growth and a forward P/E of only 13.2x, you're getting growth at a price well below the sector norm.
Bear Case
An RSI of 67.6 puts ELV in elevated territory, so a pullback to a neutral RSI could mean a 5–10% short-term drop even if fundamentals remain intact.
Catalyst to Watch
Watch for updates on government contract renewals or changes in Medicaid/Medicare policy, as these could directly shift earnings expectations.